Aeglea Bio Therapeutics Inc
Change company Symbol lookup
Select an option...
AGLE Aeglea Bio Therapeutics Inc
GME GameStop Corp
XELA Exela Technologies Inc
ARKK ARK Innovation ETF
NVVEW Nuvve Holding Equity Warrants Exp 19 March 2026 *W EXP 03/19/2026
BEPH Brookfield BRP Holdings (Canada) Inc
CHKP Check Point Software Technologies Ltd
FDX FedEx Corp
VLON Vallon Pharmaceuticals Inc
HCNEU Jaws Hurricane Acquisition Corp
Go

Health Care : Biotechnology |
Company profile

Aeglea BioTherapeutics, Inc. is a clinical-stage biotechnology company. The Company is focused on developing human enzyme therapeutics to benefit people with rare metabolic diseases. The Company’s product candidates include pegzilarginase and AGLE-177. The Company's lead product candidate, pegzilarginase, is a recombinant human arginase one that enzymatically degrades the amino acid arginine to lower arginine levels in patients with Arginase one Deficiency. Its engineered pegzilarginase with modifications that enhance the stability and arginine-degrading activity of the enzyme in human plasma. The Company is evaluating Pegzilarginase in a global pivotal Phase III PEACE (Pegzilarginase Effect on Arginase one Deficiency Clinical Endpoints) trial and in a Phase II open-label extension study for patients with Arginase One Deficiency. Its AGLE-177, is a novel PEGylated, or polyethylene glycol modified, human enzyme engineered to reduce Homocystinuria.

Closing Price
$6.00
Day's Change
-0.17 (-2.76%)
Bid
--
Ask
--
B/A Size
--
Day's High
6.21
Day's Low
5.90
Volume
(Average)
Volume:
157,454

10-day average volume:
174,612
157,454

LAWSUITS FILED AGAINST SESN, SPPI and HNST - Jakubowitz Law Pursues Shareholders Claims

2:30 pm ET October 14, 2021 (Accesswire) Print

NEW YORK, NY / ACCESSWIRE / October 14, 2021 / Jakubowitz Law announces that securities fraud class action lawsuits have commenced on behalf of shareholders of the following publicly-traded companies who purchased shares within the class periods listed below. Shareholders interested in representing the class of wronged shareholders have until the lead plaintiff deadline to petition the court. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff. For more details and to speak with our firm without cost or obligation, follow the links below.

Sesen Bio, Inc. (NASDAQ:SESN)

CONTACT JAKUBOWITZ ABOUT SESN:

https://claimyourloss.com/securities/sesen-bio-inc-loss-submission-form/?id=20450&from=1

Class Period: December 21, 2020 - August 17, 2021

Lead Plaintiff Deadline: October 18, 2021

The filed complaint alleges that defendants made materially false and/or misleading statements and/or failed to disclose that: (1) Sesen Bio's clinical trial for its cancer treatment product, Vicineum, had more than 2,000 violations of trial protocol, including 215 classified as "major"; (2) three of Sesen Bio's clinical investigators were found guilty of "serious noncompliance," including "back-dating data"; (3) Sesen Bio had submitted the tainted data in connection with the Biologics License Application ("BLA") for Vicineum; (4) Sesen Bio's clinical trials showed that Vicineum leaked out into the body, leading to side effects including liver failure and liver toxicity, and increasing the risks for fatal, drug-induced liver injury; (5) as a result of the foregoing, the Company's BLA for Vicineum was not likely to be approved; (6) as a result of the foregoing, there was a reasonable likelihood that Sesen Bio would be required to conduct additional trials to support the efficacy and safety of Vicineum; and (7) as a result of the foregoing, Defendants' positive statements about the Company's business, operations, and prospects were materially misleading and/or lacked a reasonable basis.

Spectrum Pharmaceuticals, Inc. (NASDAQ:SPPI)

CONTACT JAKUBOWITZ ABOUT SPPI:

https://claimyourloss.com/securities/spectrum-pharmaceuticals-inc-loss-submission-form/?id=20450&from=1

Class Period: December 27, 2018 - August 5, 2021

Lead Plaintiff Deadline: November 1, 2021

The filed complaint alleges that defendants made materially false and/or misleading statements and/or failed to disclose that: (i) the manufacturing facility for ROLONTIS, an investigational granulocyte-colony stimulating factor analog, maintained deficient controls and/or procedures; (ii) the foregoing deficiencies decreased the likelihood that the Food and Drug Administration would approve the ROLONTIS biologics license application ("BLA") in its current form; (iii) Spectrum had therefore materially overstated the ROLONTIS BLA's approval prospects; and (iv) as a result, the Company's public statements were materially false and misleading at all relevant times.

The Honest Company, Inc. (NASDAQ:HNST)

CONTACT JAKUBOWITZ ABOUT HNST:

https://claimyourloss.com/securities/the-honest-company-inc-loss-submission-form/?id=20450&from=1

This lawsuit is on behalf of persons and entities that purchased or otherwise acquired Honest common stock pursuant and/or traceable to the registration statement and prospectus issued in connection with the Company's May 2021 initial public offering.

Lead Plaintiff Deadline: November 15, 2021

The filed complaint alleges that defendants made materially false and/or misleading statements and/or failed to disclose that: (1) prior to the Initial Public Offering ("IPO"), the Company's results had been significantly impacted by a multimillion-dollar COVID-19 stock-up for products in the Diapers and Wipes category and Household and Wellness category; (2) at the time of the IPO, the Company was experiencing decelerating demand for such products; (3) as a result, the Company's financial results would likely be adversely impacted; and (4) as a result of the foregoing, Defendants' positive statements about the Company's business, operations, and prospects, were materially misleading and/or lacked a reasonable basis.

Image: https://www.accesswire.com/users/newswire/images/668228/image-1.png

Jakubowitz Law is vigorous in pursuit of justice for shareholders who have been the victim of securities fraud. Attorney advertising. Prior results do not guarantee similar outcomes.

CONTACT:

JAKUBOWITZ LAW

1140 Avenue of the Americas

9th Floor

New York, New York 10036

T: (212) 867-4490

F: (212) 537-5887

SOURCE: Jakubowitz Law

View source version on accesswire.com:

https://www.accesswire.com/668228/LAWSUITS-FILED-AGAINST-SESN-SPPI-and-HNST--Jakubowitz-Law-Pursues-Shareholders-Claims

comtex tracking

COMTEX_395207676/2457/2021-10-14T14:30:44

Earnings Calendar and Events Data provided by |Terms of Use| © 2021 Wall Street Horizon, Inc.

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Options are not suitable for all investors as the special risks inherent to options trading may expose investors to potentially rapid and substantial losses.
Please read Characteristics and Risks of Standard Options before investing in options.

Information and news provided by ,, , Computrade Systems, Inc., ,, and

Copyright © 2021. All rights reserved.